Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of hypertension (EMA/CHMP/29947/2013/Rev.4)

Day 80 assessment report - Clinical template with guidance - Rev. 10.26 - Revamp

Methodological Principles for the Assessment of Section 5.1 of the Summary of Product Characteristics

Methodological Principles for the Assessment of Section 5.1 of the Summary of Product Characteristics

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, Date of authorisation: 09/12/2021, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Date of authorisation: 25/08/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Plegridy, peginterferon beta-1a, Date of authorisation: 18/07/2014, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): HyQvia, human normal immunoglobulin, Date of authorisation: 16/05/2013, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 28, Status: Authorised